The ENA (Extractable Nuclear Antigen) profile is a collection of tests used to detect specific autoantibodies targeting various proteins and ribonucleoproteins within the cell nucleus. These antibodies are associated with autoimmune diseases like lupus, scleroderma, and others.

It help diagnose certain autoimmune diseases.

10 to 15 are considered equivocal

The ENA (Extractable Nuclear Antigen) Profile test is a blood test that detects the presence of specific antibodies directed against various nuclear antigens. These antibodies are associated with autoimmune diseases, particularly systemic autoimmune rheumatic diseases (SARDs) such as systemic lupus erythematosus (SLE), Sjögren's syndrome, systemic sclerosis (scleroderma), and mixed connective tissue disease (MCTD). Here's how to interpret the results: Positive Results: A positive ENA profile indicates the presence of antibodies against one or more nuclear antigens. Interpretation: The specific pattern of antibodies detected in the ENA profile can help differentiate between different autoimmune diseases. For example, the presence of anti-dsDNA antibodies is highly suggestive of SLE, while anti-Sm antibodies are specific for SLE. Other antibodies detected in the ENA profile may be associated with specific autoimmune diseases: Anti-SSA (Ro) and anti-SSB (La) antibodies are associated with Sjögren's syndrome and SLE. Anti-Scl-70 antibodies are associated with systemic sclerosis (scleroderma). Anti-U1RNP antibodies are associated with mixed connective tissue disease (MCTD). Anti-Jo-1 antibodies are associated with polymyositis and dermatomyositis. Clinical Correlation: Interpretation of the ENA profile results should be done in conjunction with the patient's clinical history, symptoms, physical examination findings, and other laboratory tests. The presence of specific antibodies may help support a diagnosis of an autoimmune disease but should not be used in isolation for diagnosis. Disease Monitoring: Serial monitoring of ENA profile results may be useful in assessing disease activity, response to treatment, and risk of disease flares in patients with autoimmune diseases. False Positives and False Negatives: It's important to consider that false-positive and false-negative results can occur with ENA testing. False-positive results may occur due to non-specific binding or cross-reactivity of antibodies. False-negative results may occur if the patient is in the early stages of the disease or if the antibody levels are below the detection threshold of the assay. Confirmation and Further Testing: Positive ENA profile results may warrant further confirmatory testing, such as additional antibody tests or referral to a rheumatologist for further evaluation and management. Other diagnostic tests, such as imaging studies, biopsy, or clinical assessment of organ involvement, may also be necessary to establish a diagnosis and guide treatment. Interpretation of the ENA profile test results should be performed by healthcare providers experienced in the diagnosis and management of autoimmune diseases. It's essential to consider the clinical context, symptoms, and other relevant factors when interpreting test results and determining appropriate treatment and management strategies.

Blood